Project information
MEDGENET - Medical genomics and epigenomics network
(MEDGENET)
- Project Identification
- 692298
- Project Period
- 1/2016 - 12/2018
- Investor / Pogramme / Project type
-
European Union
- Horizon 2020
- Spreading excellence and widening participation
- MU Faculty or unit
- Central European Institute of Technology
- Cooperating Organization
-
European Molecular Biology Laboratory
Uppsala universitet
Centre for Research and Technology Hellas
The main goal of MEDGENET consortium is to use synergies and existing expertise in EU leading institutions such as EMBL, Uppsala University and CERTH to reinforce the productivity and competitiveness of the CEITEC in the field of medical genomics and epigenomics. We propose clear strategy based on combination of unique complementary skills present in partner institutions that will transform CEITEC into a key leader in the field. ERA Chair who recently joint CEITEC already initiated the transformational change of the institute and TWINNING framework will further support sharing her international contacts with other CEITEC researchers. MEDGENET aims to create well-educated taskforce of biomedical researchers, who will notably contribute to the development of new genomics and bioinformatics tools and their application in clinical practice. Proposed project will enable to establish the best practices for performing innovative and high-quality biomedical research and to strengthen CEITEC´s competence to translate the research results into high value-added clinical applications. Stimulation of knowledge exchange, implementation of cutting edge technologies and mastery of modern genomics and bioinformatics methodologies will have a direct impact on the overall research and innovation potential of CEITEC and will increase its visibility in the international scientific community.
Publications
Total number of publications: 53
2018
-
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets 1 and 2 treated with chemo(immuno)therapy
haematologica, year: 2018, volume: 103, edition: 4, DOI
-
Promoter methylation of ROR1 ligand WNT5A associates with its expression in CLL
Year: 2018, type: Conference abstract
-
ToTem: a tool for variant calling pipeline optimization
BMC Bioinformatics, year: 2018, volume: 19, edition: JUN, DOI
-
Tracking the minor clones in oligoclonal chronic lymphocytic leukemia using high-throughput immunoprofiling
Year: 2018, type: Conference abstract
2017
-
Basic domain of telomere guardian TRF2 reduces D-loop unwinding whereas Rap1 restores it
Nucleic Acids Research, year: 2017, volume: 45, edition: 21, DOI
-
BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.
Year: 2017, type: Conference abstract
-
Biallelic TP53 gene mutations due to copy-neutral loss of heterozygosity and monoallelic mutations in absence of 17p deletion occur in CLL with comparable frequency
Year: 2017, type: Conference abstract
-
Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies
Year: 2017, type: Conference abstract
-
GLASS
Year: 2017
-
GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data
Bioinformatics, year: 2017, volume: 33, edition: 23, DOI